Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer

HRD subtyping refines risk stratification beyond traditional TCGA classification and identifies patients potentially responsive to immune checkpoint or DNA damage-targeted therapies. Integrating HRD-based genomic instability metrics with molecular and immune profiling supports precision oncology in endometrial cancer.